We hybridized Raji
In Burkitt lymphomas with t(8;14) translocations, the cellular myc oncogene, c-myc, which is normally on band q24 of chromosome 8 (1) (2) (3) (4) , translocates to the heavy (H) chain locus (1, 3, 4) on chromosome 14 (5) . In Burkitt lymphomas with variant t(8;22) and t(2;8) chromosome translocations, the c-myc gene remains in its germ-line configuration on the involved chromosome 8 (8q+), while either the A or the K light chain locus translocates to a region distal (3' ) to the involved c-myc oncogene (6, 7) . The consequence of these different types ofrearrangements is deregulation oftranscription ofthe involved c-myc oncogene, which is expressed constitutively at elevated levels (6) (7) (8) in the lymphomas. Since c-myc deregulation or, in other terms, constitutive c-myc expression is a possible initial cause of these lymphomas, there is great interest in arriving at an understanding of the mechanism(s) of constitutive c-myc expression. The first obvious common denominator in the lymphoma is the translocation itself, which juxtaposes a c-myc gene and an immunoglobulin locus; the second common denominator is that the involved c-myc locus in cases thus far analyzed is always 5 ' ofthe involved immunoglobulin locus; and the third common denominator, aside from the constitutive expression of the involved c-myc gene, is the silence or near silence of the untranslocated c-myc allele in the lymphomas (8, 9) .
These common denominators may serve as clues in unraveling the mechanism(s) responsible for constitutive expression of the involved c-myc allele, but the heterogeneity of the breakpoints on chromosome 8 and within the immunoglobulin loci have led to differing proposals to explain constitutive c-myc expression. Because in many cases of Burkitt lymphoma with the t (8;14) translocation the c-myc oncogene translocates to a H-chain switch (S) region (predominantly S,) on the 14q+ chromosome, with concomitant translocation of the immunoglobtilin H-chain gene (IGH) enhancer [located between the H-chain joining region (JH) and the So region] to the 8q-chromosome, it has been speculated that c-myc activation in Burkitt lymphoma is not the result of transcriptional enhancement (10, 11) . Leder et al. (10) have proposed that the first exon of the c-myc oncogene and regions 5' to the first exon mediate negative regulation of c-myc transcription by binding to a putative repressor protein. According to this model, truncation of the c-myc oncogene at its 5' end or changes in its 5' exon would affect the binding of the putative repressor to the c-myc gene, resulting in its deregulation (10, 11) ; thus, the translocated c-myc gene would be insensitive to negative regulation (10, 11) . Since we observed that a 5'-truncated and translocated c-myc oncogene is not expressed (i.e., not deregulated) when introduced into fibroblasts (12) , it seemed unlikely that loss of the c-myc first exon is responsible per se for c-myc deregulation. These studies and others to be discussed below demonstrated that the constitutive expression of the translocated c-myc allele was observed only in a B-cell background; i.e., activation of the c-myc gene involved in the different chromosomal translocations was B-cell specific (8, (12) (13) (14) .
If constitutive c-myc expression from the translocated (or involved) c-myc allele were due solely to loss of or change in certain regulatory signals normally contained within or 5' of the c-myc gene so that the involved allele could no longer respond to negative regulation, one would expect the involved c-myc allele to remain activated even when placed within a phenotypically different cell type. Thus, we have proposed that the constitutive expression of the involved c-myc allele in Burkitt lymphomas must be due to B-cell stage-specific, cis-acting, positive-regulatory elements within the immunoglobulin loci (13, 14) .
In previous studies (15, 16) , two Burkitt lymphoma cell lines, ST486 and CA46, in which the coding portion of the 5'-truncated c-myc gene (lacking its 5' exon) is translocated respectively to the S., or the Sa region, were hybridized with human lymphoblastoid cells; the hybrids retained the lymphoblastoid phenotype and expressed the normal but not the translocated c-myc gene (13) . From these results we concluded that the translocated c-myc gene is under the control of thus far unidentified genetic elements within the H-chain locus capable of enhancing c-myc transcription in Burkitt lymphoma cells and plasma cells, but incapable of activating gene transcription in lymphoblastoid cells (13 (14) . Interestingly, we observed that the hybrid cells expressed both the normal and the translocated c-myc genes. These results indicate that genetic elements 5' of S, (possibly the immunoglobulin H-chain gene enhancer between S. and JH) are capable of activating c-myc transcription not only in Burkitt lymphoma cells and plasma cells but also in lymphoblastoid cells (14) . Thus, it seems likely that Burkitt-like translocations lead to malignant transformation by deregulation of c-myc transcription due to proximity to different genetic elements capable of enhancing gene transcription, some of which are more "promiscuous" and can activate gene transcription in B cells at different stages of B-cell differentiation from pre-B-cells (17) to plasma cells (13, 14) , while others are able to activate gene transcription only in the more differentiated B cells (13) .
In this study we intended to assess the role of changes in the first c-myc exon in the deregulation of the c-myc gene. Therefore, we hybridized human lymphoblastoid cells with Raji cells which carry a translocated c-myc gene that is mutated in its 5' exon (11) . If changes in the c-myc 5' exon or its flanking sequence were responsible for c-myc activation in Raji cells, we should observe expression of the translocated c-myc gene in the hybrids. On the contrary, if the genetic elements that are responsible for translocated c-myc activation in ST486 and CA46 cells are involved in the enhancement of expression of the translocated Raji c-myc gene, we should not observe translocated c-myc transcription in lymphoblastoid hybrid cells, since the putative enhancer elements that are active in CA46 and ST486 Burkitt lymphoma cells are not active in human lymphoblastoid cells (13) . S1 Protection Experiment. Twenty micrograms of cytoplasmic RNAs prepared from various cell lines were subjected to S1 nuclease mapping analysis (20) . The M13 clone containing the genomic c-myc DNA insert, encompassing the region surrounding the two promotors and the first exon of the c-myc gene, was used as an S1 probe. The uniformly 32P-labeled DNA (21) was heat-denatured, hybridized in 80% formamide to the various RNA samples at 65.50C for 10 hr, digested with S1 nuclease, and analyzed by electrophoresis on a 7 M urea/4% polyacrylamide gel as described (22) .
MATERIALS AND METHODS
Cells. The GM1500-6TG-OUB cells are derived from the hypoxanthine phosphoribosyltransferase-deficient GM1500-6TG human lymphoblastoid cells and are resistant to 100 ,uM ouabain (13) . GM1500A-6TG cells are a late passage of the GM1500-6TG cell line. The difference in levels of c-myc transcripts in the GM1500-6TG-OUB and GM1500-6TG has been reported (13) . GM1500-6TG-OUB cells carry a germ line c-myc gene (13), do not carry constant region p.-chain gene (C.) sequences, and express IgG (Y2 and K chains) (13) . Raji cells are derived from an African Burkitt lymphoma with the t(8;14) translocation and carry a translocated c-myc oncogene on the 14q+ chromosome (11) . Following fusion with polyethylene glycol, the hybrids were selected in HAT medium (hypoxanthine/aminopterin/thymidine) containing 10 ,uM ouabain by standard procedures (13) . The Burkitt lymphoma cell lines ST486, CA46, Manca, Daudi, and P3HR-1 carrying the t(8;14) chromosome translocation and lines BL2 and JI carrying respectively the t(8;22) or t(2;8) chromosome translocation have been described (1, 3, 6-9, 13-15). The two additional Burkitt lymphomas Ag876 and EW36 with the t(8;14) translocation were a kind gift of Ian McGrath (National Cancer Institute).
Southern Blotting Analysis. Parental and hybrid cell DNAs were digested with restriction enzymes, fractionated by (0.7% or 1%) agarose gel electrophoresis, and blotted to nitrocellulose filters essentially as described by Southern (18) . The agarose gel electrophoresis was carried out in 40 mM Tris.HCl/5 mM NaOAc/EDTA, pH 8.0. HindIII-digested X phage DNA molecular weight markers (1.0 ,g per lane) (Bethesda Research Laboratories) were included on every gel (13) . The EcoRI 1.2-kilobase (kb) genomic C,,, the JH, and the c-myc cDNA (Ryc 7.4) probes used in this study have been described (3, 13) . The DNA probes were labeled by the nick-translation procedure (19) .
RESULTS
Lymphoblastoid-Raji Hybrids Retain the Lymphoblastoid Phenotype. We hybridized Raji cells and GM1500-6TG-OUB cells at the ratio of 1:1 in the presence of polyethylene glycol (13) . The hybrids were selected as described (13) . Approximately 95 independent hybrid colonies were obtained by hybridizing 107 GM1500-6TG-OUB cells with 107 Raji cells. Four independent colonies were picked up and expanded. The four hybrids (AB2, DB2, CA2, and BD5) retained the JH segments ofboth GM1500-6TG-OUB and Raji parental cells ( Fig. 1 and Table 1 ). The hybrids also retained the CM gene of Raji cells (Fig. 2 and Table 1 ). Phenotypically, the hybrids resembled the GM1500-6TG-OUB lymphoblastoid parental cells and grew in large clumps. On the contrary, Raji cells grew as single cells. We also tested the hybrid cells tThe expression of the antigen was detected munofluorescence as described (13, 23) .
by indirect imGenetics: Nishikura et al. for the presence of a surface antigen that is expressed on human lymphoblastoid cells but not in several human Burkitt lymphoma cells (23) . This antigen is recognized by a murine monoclonal antibody (B532) (24 (12, 14, 23) . The hybrids also were examined for the presence of the normal and of the translocated c-myc gene. All four hybrids retained both the normal and the translocated c-myc genes (13.5-and 23-kb bands in Fig. 3 and Table 1 ), indicating that they had retained the 14q+ chromosome derived from the Raji Burkitt lymphoma cells.
Expression of c-myc Transcripts in Hybrid Cells. Rabbits et al. have shown mutations in the translocated c-myc gene of Raji cells (11) . These mutations involve the c-myc first exon, the first intron, and the second c-myc exon (11) . Some of these structural alterations can be detected by carrying out S1
nuclease protection experiments using a first-exon probe of the human c-myc oncogene (14) . By using a first-exon probe, we detected altered c-myc transcripts as 440-and 270-nucleotide S1 nuclease-resistant DNA products in Raji cells (Fig. 4A, lane 6) , whereas the normal c-myc transcripts generated 515-and 350-nucleotide products corresponding to the RNAs initiated from the first and second cap site, respectively, in human lymphoblastoid cells (Fig. 4A, lane 7) . Interestingly we also observed normal c-myc transcripts in Raji cells (Figs. 4 and 5) . However, the level of normal c-myc transcripts in Raji cells was less than 2% of the level of translocated c-myc transcripts (Figs. 4 and 5 (11) .
By S1 nuclease analysis we also detected alteration in the myc 5' exon of other Burkitt lymphoma cells with t(8;14) translocations such as Daudi and P3HR-1 (Fig. 4A) . We did not detect myc 5' exon changes in Ag876 and EW36 Burkitt lymphomas with t(8;14) translocations (Fig. 4A) . Leder et al. have reported that Burkitt lymphomas utilize predominantly the first promoter of the c-myc oncogene and that this might be important in malignant transformation (10). We did not observe a preferential utilization of the first c-myc promoter in Ag876 and EW36 Burkitt lymphoma cells (Fig. 4A) . Therefore, we analyzed several Burkitt lymphomas with the three different Burkitt chromosome translocations. Some cell lines indeed utilized the first promoter more frequently while others did not. Interestingly, the aberrant c-myc transcripts derived from the translocated c-myc first exon on the 8q-chromosome (9) also utilized the first promoter more extensively (ST486 and JD38; Fig. 4B, lanes 2 and 3) Since we could distinguish between the expression of the translocated c-myc gene of Raji cells versus the normal c-myc gene (Fig.  4A , lane 6 versus lane 7), we used the first exon probe to determine whether the hybrids express the Raji translocated c-myc gene. The translocated c-myc gene of Raji cells is completely silent in the lymphoblastoid hybrids because only the 515-and 350-nucleotide products corresponding to the RNAs initiated at the first and second cap sites were observed in the hybrids (Fig. 5) . On the contrary, the normal c-myc gene was expressed at levels comparable to the level expressed in GM1500-6TG human lymphoblastoid cells. The levels of normal c-myc transcripts in these cells were lower than the level expressed in the GM1500-6TG-OUB doublemutant cells (13) , suggesting that complementation with Raji cells results in the reduction of the level of expression of the over-expressed c-myc gene of GM1500-6TG-OUB cells. These results indicate that an activated c-myc oncogene with a mutated 5' exon that has been translocated to aS region and is expressed at high levels in Burkitt lymphoma cells becomes transcriptionally silent in a lymphoblastoid cell background.
DISCUSSION
In Raji Burkitt lymphoma cells, the translocated c-myc gene is mutated in its 5' exon and is expressed at elevated levels, while the normal c-myc gene is expressed at low levels. Since in Raji cells the c-myc gene is translocated to a Sly region (11), the immunoglobulin H-chain gene enhancer normally located between JH and S, is not located in front of the translocated c-myc gene on the 14q+ chromosome but is translocated to the 8q-chromosome. Thus, the immunoglobulin H-chain gene enhancer cannot be involved in activation of the translocated c-myc gene.
Are the structural alterations in the c-myc 5' exon responsible for translocated c-myc activation as suggested by Leder et al. (10) ? Clearly the results of the experiments described in this paper indicate that structural alterations in the 5' exon of the c-myc oncogene and/or 5' of the c-myc oncogene are not responsible per se for c-myc activation, since no expression of the translocated c-myc oncogene is detectable in human lymphoblastoid cells.
These results are consistent with our previous findings that a 5'-truncated c-myc oncogene translocated to a S region of the H-chain gene is silent in lymphoblastoid cells (13) . Thus, is seems that it does not make much difference whether the translocated c-myc gene is 5'-truncated or not. What seems to be important in the differential regulation of the translo- (23, 25) and the acute lymphocytic leukemia with the double translocation discussed above (17) Burkitt lymphomas in which c-myc is activated by proximity to light chain immunoglobulin loci fall into similar classes.
In conclusion, by somatic cell hybridization studies, we have been able to broadly define the B-cell stage specificity of transcriptional c-myc activation as a positive-regulatory event involving interaction -f trans-acting factors with cis sequences (cis to myc) within the H-chain locus. To narrow the search for the putative cis sequences will require transfection of large, rearranged c-myc: H-chain gene molecular clones into cells of the more differentiated stages of the B-cell lineage.
